The recent approval of omaveloxolone for the treatment of Friedreich ataxia in the USA and Europe represents an important milestone in the field of rare neurological diseases. However, many challenges lie ahead, including the translation of trial results into clinical practice, and the management of patients’ expectations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boesch, S. & Indelicato, E. Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials. Expert Opin. Investig. Drugs 32, 967–969 (2023).
Indelicato, E. et al. Onset features and time to diagnosis in Friedreich’s ataxia. Orphanet J. Rare Dis. 15, 198 (2020).
Indelicato, E. et al. Predictors of survival in Friedreich’s ataxia: a prospective cohort study. Mov. Disord. 39, 510–518 (2024).
Indelicato, E. & Bösch, S. Emerging therapeutics for the treatment of Friedreich’s ataxia. Expert Opin. Orphan Drugs 6, 57–67 (2018).
Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann. Neurol. 89, 212–225 (2021).
Lynch, D. R. et al. Efficacy of omaveloxolone in Friedreich’s ataxia: delayed-start analysis of the MOXIe extension. Mov. Disord. 38, 313–320 (2023).
Lynch, D. R. et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann. Clin. Transl. Neurol. 11, 4–16 (2024).
Karthikeyan, G. et al. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 12, 3331–3342 (2003).
Singh, I. et al. Investigation of mitochondrial DNA variations among Indian Friedreich’s ataxia (FRDA) patients. Mitochondrion 25, 1–5 (2015).
Indelicato, E. et al. Skeletal muscle proteome analysis underpins multifaceted mitochondrial dysfunction in Friedreich’s ataxia. Front. Neurosci. 17, 1289027 (2023).
Acknowledgements
S.B. and E.I. are members of the European Reference Network for Rare Neurological Diseases — project ID 739510.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.B. reports consultancy activity for VICO Therapeutics, REATA Pharmaceutics and Biogen, advisory board activity for REATA Pharmaceutics and Biogen, and honoraria from Ipsen, Merz Pharma, Abbvie, REATA Pharmaceutics and Biogen. E.I. declares no competing interests.
Additional information
Related links
Friedreich’s Ataxia Treatment Pipeline: https://www.curefa.org/research/research-pipeline
Rights and permissions
About this article
Cite this article
Boesch, S., Indelicato, E. Approval of omaveloxolone for Friedreich ataxia. Nat Rev Neurol (2024). https://doi.org/10.1038/s41582-024-00957-9
Published:
DOI: https://doi.org/10.1038/s41582-024-00957-9